Anti-cancer effects of celecoxib in head and neck carcinoma

Molecules and Cells

Volumn 29, Issue 2, 2010, Pages 185-194

  Kim, Young Youn ^a   Lee, Eun Jin ^a   Kim, Yu Kyoung ^a   Kim, Soung Min ^a   Park, Ju Yong ^b   Myoung, Hoon ^a   Kim, Myung Jin ^a  

^a Seoul National University   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Angiogenesis; Celecoxib; Cyclooxygenase2 (COX2); Head and neck carcinoma (HNC); Invasion; Oral squamous cell carcinoma

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; SURVIVIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; HAMSTER; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CHEMOPREVENTION; CRICETINAE; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MESOCRICETUS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM INVASIVENESS; PYRAZOLES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

CRICETINAE;

EID: 77949422843     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10059-010-0026-y     Document Type: Article

References (55)

1. Attiga, F.A., Fernandez, P.M., Weeraratna, A.T., Manyak, M.J., and Patierno, S.R. (2000). Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 60, 4629-4637.
2. Barnes, N., Haywood, P., Flint, P., Knox, W.F., and Bundred, N.J. (2006). Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Brit. J. Cancer 94, 253-258.
3. Bartsch, H. (2000). Studies on biomarkers in cancer etiology and prevention: a summary and challenge of 20 years of interdisciplinary research. Mutat. Res. 462, 255-279.
4. Bartsch, H., and Nair, J. (2000). Ultrasensitive and specific detection methods for exocylic DNA adducts: markers for lipid peroxidation and oxidative stress. Toxicology 153, 105-114.
5. Bernardo, M.M., and Fridman, R. (2003). TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem. J. 374, 739-745.
6. Bosari, S. (1992). Microvessel quantitation and prognosis in invasive breast carcinoma, Hum. Pathol. 23, 755-761.
7. Chan, T.A. (2002). Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet. Oncol. 3, 166-174.
8. Chan, G., Boyle, J.O., Yang, E.K., Zhang, F., Sacks, P.G., Shah, J.P., Edelstein, D., Soslow, R.A., Koki, A.T., Woerner, B.M., et al. (1999). Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59, 991-994.
9. Crowell, P.L., Schmidt, C.M., Yip-Schneider, M.T., Savage, J.J., Hertzler, II D.A., and Cummings, W.O. (2006). Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. Neoplasia 8, 437-445.
10. Dannenberg, A.J., Altorki, N.K., Boyle, J.O., Dang, C., Howe, L.R., Weksler, B.B., and Subbaramaiah, K. (2001). Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2, 544-551.
11. Duffy, M.J., O'Donovan, N., Brennan, D.J., Gallagher, W.M., and Ryan, B.M. (2007). Survivin: a promising tumor biomarker. Cancer Lett. 249, 49-60.
12. Dvory-Sobol, H., Cohen-Noyman, E., Kazanov, D., Figer, A., Birkenfeld, S., Madar-Shapiro, L., Benamouzig, R., and Arber, N. (2006). Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur. J. Cancer. 42, 422-426.
13. Edwards, J., Mukherjee, R., Munro, A.F., Wells, A.C., Almushatat, A., and Bartlett, J.M. (2004). HER2 and COX2 expression in human prostate cancer. Eur. J. Cancer 40, 50-55.
14. Erkanli, S., Bolat, F., Kayaselcuk, F., Demirhan, B., and Kuscu, E. (2007). COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol. Oncol. 104, 320-325.
15. Feng, L., and Wang, Z. (2006). Chemopreventive effect of celecoxib in oral precancers and cancers. Laryngoscope 116, 1842-1845.
16. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82, 4-6.
17. Folkman, J., and Shing, Y. (1992). Angiogenesis. J. Biol. Chem. 267, 10931-10934.
18. Gleich, L.L., Zimmerman, N., Wang, Y.O., and Gluckman, J.L. (1998). Angiogenic inhibition for the treatment of head and neck cancer. Anticancer Res. 18, 2607-2609.
19. Goodin, S., and Shiff, S.J. (2004). NSAIDs for the chemoprevention of oral cancer: promise or pessimism? Commentary re J.L. Mulshine et al., randomized, double-blind, placebocontrolled, phase IIB trial of the cyclooxygenase inhibitor Ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin. Cancer Res. 10, 1565-1573.
20. Hao, Y., Xie, T., Korotcov, A., Zhou, Y., Pang, X., Shan, L., Ji, H., Sridhar, R., Wang, P., Califano, J., et al. (2009). Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways. Int. J. Cancer 124, 2200-2209.
21. Harris, R.E. (2007). Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell. Biochem. 42, 93-126.
22. Haupt, S., Kleinstern, J., Haupt, Y., and Rubinstein, A. (2006). Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species. Anti-Cancer Drugs 17, 609-619.
23. Hsue, S.S., Chen, Y.K., and Lin, L.M. (2008). Expression of survivin and XIAP for DMBA-induced hamster buccal pouch squamous cell carcinogenesis is associated with p53 accumulation. Oral Oncol. 44, 43-49.
24. Inoue, H., Yokoyama, C., Hara, S., Tone, Y., and Tanabe, T. (1995). Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J. Biol. Chem. 270, 24965-24971.
25. Johnstone, S., and Logan, R.M. (2006). The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. Oral Oncol. 42, 337-342.
26. Kennedy, S.M., O'Driscoll, L., Purcell, R., Fitz-Simons, N., Mc-Dermott, E.W., and Hill, A.D. (2003). Prognostic importance of survivin in breast cancer. Br. J. Cancer 88, 1077-1083.
27. Kinugasa, Y., Hatori, M., Ito, H., Kurihara, Y., Ito, D., and Nagumo, M. (2004). Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via downregulation of matrix metalloproteinase-2 and CD44. Clin. Exp. Metastasis 21, 737-745.
28. Kulp, S.K., Yang, Y.T., Hung, C.C., Chen, K.F., Lai, J.P., Tseng, P.H., Fowble, J.W., Ward, P.J., and Chen, C.S. (2004). 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 64, 1444-1451.
29. Lai, G.H., Zhang, Z., and Sirica, A.E. (2003). Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol. Cancer Ther. 2, 265-271.
30. Le Bitoux, M.A., and Stamenkovic, I. (2008). Tumor-host interactions: the role of inflammation. Histochem. Cell Biol. 130, 1079-1090.
31. Lerebours, F., Vacher, S., Andrieu, C., Espie, M., Marty, M., Lidereau, R., and Bieche, I. (2008). NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 4, 8-41.
32. Liu, C.H., Chang, S.H., Narko, K., Trifan, O.C., Wu, M.T., Smith, E., Haudenschild, C., Lane, T.F., and Hla, T. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276, 18563-18569.
33. Maeda, S., and Omata, M. (2008). Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 99, 836-842.
34. Maier, T.J., Schilling, K., Schmidt, R., Geisslinger, G., and Grösch, S. (2004). Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 67, 1469-1478.
35. Mann, J.R., Backlund, M.G., and DuBois, R.N. (2005). Mechanisms of Disease: inflammatory mediators and cancer prevention. Nat. Clin. Pract. Oncol. 2, 202-210.
36. Mohan, S., and Epsteina, J.B. (2003). Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol. 39, 537-546.
37. Mori, F., Piro, F.R., Rocca, C.D., Mesiti, G., Giampaoli, S., Silvestre, G., and Lazzaro, D. (2007). Survivin and Cyclooxygenase-2 are co-expressed in human and mouse colon carcinoma and in terminally differentiated colonocytes. Histol. Histopathol. 22, 61-77.
38. Ouhtit, A., Matrougui, K., Bengrine, A., Koochekpour, S., Zerfaoui, M., and Yousief, Z. (2007). Survivin is not only a death encounter but also a survival protein for invading tumor cells. Front. Biosci. 12, 1260-1270.
39. Park, M.K., Hwang, S.Y., Kim, J.O., Kwack, M.H., Kim, J.C., Kim, M.K., and Sung, Y.K. (2004). NS398 inhibits the growth of Hep3B human hepatocellular carcinoma cells via caspaseindependent apoptosis. Mol. Cells 17, 45-50.
40. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics 2002. CA Cancer J. Clin. 55, 74-108.
41. Pyrko, P., Soriano, N., Kardosh, A., Liu, Y.T., Uddin, J., Petasis, N.I., Hofman, F.M., Chen, C.S., Chen, T.C., and Schönthal, A.H. (2006). Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol. Cancer 18, 5.19.
42. Ristimaki, A., Honkanen, N., Jankala, H., Sipponen, P., and Harkonen, M. (1997). Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57, 1276-1280.
43. Ristimaki, A., Nieminen, O., Saukkonen, K., Hotakainen, K., Nordling, S., and Haglund, C. (2001). Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am. J. Pathol. 158, 849-853.
44. Sheng, H., Shao, J., Dixon, D.A., Williams, C.S., Prescott, S.M., DuBois, R.N., and Beauchamp, R.D. (2000). Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J. Biol. Chem. 275, 6628-6635.
45. Shin, S., Sung, B.J., Cho, Y.S., Kim, H.J., Ha, N.C., Hwang, J.I., Chung, C.W., Jung, Y.K., and Oh, B.H. (2001). An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40, 1117-1123.
46. Steinbach, G., Lynch, P.M., Phillips, R.K., Wallace, M.H., Hawk, E., Gordon, G.B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952.
47. Tang, D.W., Lin, S.C., Chang, K.W., Chi, C.W., Chang, C.S., and Liu, T.Y. (2003). Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma--evidence for COX-2 induction by areca quid ingredients in oral keratinocytes. J. Oral Pathol. Med. 32, 522-529.
48. Ulrich, C.M., Bigler, J., and Potter, J.D. (2006). Non-steroidal antiinflammatory drugs for cancer prevention, promise, perils, and pharmacogenetics. Nat. Rev. Cancer 6, 130-140.
49. Wang, Z., Fuentes, C.F., and Shapshay, S.M. (2002). Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 112, 839-843.
50. Wilson, K.T., Fu, S., Ramanujam, K.S., and Meltzer, S.J. (1998). Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 58, 2929-2934.
51. Woolgar, J.A., Rogers, S.N., Lowe, D., Brown, J.S., and Vaughan, E.D. (2003). Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncol. 39, 130-137.
52. Yamazaki, R., Kusunoki, N., Matsuzaki, T., Hashimoto, S., and Kawai, S. (2002). Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 531, 278-284.
53. Yang, C., Zeisberg, M., Lively, J.C., Nyberg, P., Afdhal, N., and Kalluri, R. (2003). Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 63, 8312-8317.
54. Yang, W.T., Lewis, M.T., and Hess, K. (2010). Decreased TGF beta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res. Treat. 119, 305-314.
55. Zimmermann, K.C., Sarbia, M., Weber, A.A., Borchard, F., Gabbert, H.E., and Schrör, K. (1999). Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59, 198-204.